In an amicus brief submitted to the Supreme Court, AAM called on the court to reject one form of patent system manipulation attempted by a brand-name drug company. AAM’s brief emphasizes the extent to which Helsinn’s interpretation of the on-sale bar would invite manipulation and foster confusion in the pharmaceutical market, with deleterious consequences for patients, taxpayers, and others who seek more affordable medicines.
![](/sites/default/files/styles/hero/public/2017-12/amicus%20brief%20-%20stock.jpg?h=397da195&itok=6wR3BiXA)
![](/sites/default/files/styles/hero_tablet/public/2017-12/amicus%20brief%20-%20stock.jpg?h=397da195&itok=9P2Wn0zz)
![](/sites/default/files/styles/hero_mobile/public/2017-12/amicus%20brief%20-%20stock.jpg?h=397da195&itok=WMrlNKGw)